The DOI matches its Crossref record; 268 of the 271 references it cites were found in a registry or an index.
American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
Abstract
INTRODUCTION Irritable bowel syndrome (IBS) is the most prevalent of the functional gastrointestinal disorders (FGIDs). Current estimates are that IBS affects up to 10–12% of adults in North America [1, 2]. Although it can affect all individuals regardless of age, creed, or gender, IBS is more common among women and is most commonly diagnosed in younger individuals ( 0.10 for the ÷2 test, was arbitrarily chosen to represent low levels of heterogeneity [29]. Review Manager version 5.3.5 (RevMan for Windows 2014, The Nordic Cochrane Centre, Copenhagen, Denmark) was used to generate Forest plots of pooled RRs and SMDs for primary and secondary outcomes with 95% CIs, as well as funnel plots. The latter were assessed for evidence of asymmetry, and therefore possible publication bias or other small study effects, using the Egger test [30], if there were sufficient (10 or more) eligible studies included in the meta-analysis, in line with published recommendations [31]. GRADEpro version 3.6 (GRADE working group 2004–2007) was used to grade the quality of the evidence. Consensus was reached using a consensus-oriented decision-making framework [32], culminating in a face-to-face meeting to discuss the evidence and reach a unanimous decision on the quality of evidence and strength of recommendation. EXERCISE, DIET AND DIETARY MANIPULATION Exercise We suggest exercise for overall symptom improvement in IBS patients. (Recommendation: weak; Quality of Evidence: very low) Exercise and physical fitness are key elements of maintaining physical and mental health [33, 34]. Studies from healthy volunteers and patients suggest that physical activity protects against gastrointestinal (GI) symptoms [35, 36], and bears an inverse relationship with colonic transit time [37]. Based upon these observations, it is reasonable to hypothesize that exercise might be beneficial to patients with IBS. To date, there have been few RCTs that have rigorously evaluated the benefits of exercise in IBS patients. Daley et al. invited 305 IBS patients to participate in a RCT that compared 12 weeks of an exercise intervention with usual care [38]. Fifty-six IBS patients (18%) agreed to participate. Quality of life (IBS-QOL) and IBS symptoms (Birmingham IBS symptoms questionnaire) were assessed before and after the interventions. Exercise led to statistically significant benefits for constipation (95% CI: -1.6 to -20.1) but not for other outcomes such as abdominal pain, diarrhea, total symptom score, or quality of life. In a second trial, Johannesson et al. randomized 102 IBS patients to a rigorous exercise program monitored by a physiotherapist or usual care for 12 weeks [39]. Seventy-five IBS patients completed the trial. IBS symptom severity scores improved to a greater degree in the exercise arm compared with the control arm (P = 0.003). The same authors reported long-term follow-up data (median follow-up 5.2 years) for 39 of the originally enrolled IBS patients [40]. Increases in physical activity and improvements in symptom scores compared with baseline were maintained at follow-up. Summary. Although it is clear that exercise offers general health benefits and, whenever possible, should be encouraged the Task Force did not feel that the weight or strength of available evidence justified a strong recommendation regarding exercise for IBS. Although encouraging, the Task Force feels that the current body of evidence should be viewed as hypothesis-generating, and in need of validation by methodologically rigorous, appropriately powered, RCTs. Diet and dietary manipulation for IBS We suggest a low FODMAP diet for overall symptom improvement in IBS patients. (Recommendation: weak; Quality of evidence: very low) We suggest against a gluten-free or exclusion diet based upon antibody or leukocyte activation test for overall symptom improvement in IBS patients. (Recommendation: weak; Quality of evidence: very low) The majority of IBS patients associate symptom onset or worsening with eating a meal. Although true food allergy is uncommon in IBS patients, perceived food intolerances or sensitivities are quite common. Up to 90% of IBS patients exclude certain foods in the hopes of avoiding or improving their GI symptoms [41]. Since the publication of the last IBS Task Force evidence-based review in 2014 [4], there have been numerous studies that have evaluated dietary therapies in IBS patients [42]. Although various diets have been suggested to benefit IBS patients, the largest body of evidence relates to two specific diets; a diet low in fermentable oligo-saccharides, di-saccharides, and mono-saccharides, and polyols (FODMAPs) and a gluten-free diet. We identified seven eligible RCTs (evaluating 397 participants) that provided dichotomous outcomes for a low FODMAP diet versus an alternative diet [43–49]. There was an overall effect of the low FODMAP diet in reducing IBS symptoms with a RR of remaining symptomatic on a low FODMAP diet of 0.69 (95% CI 0.54 to
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the drug improved stool frequency and consistency, it had no effect on global symptoms (RR 0.44; 95% CI 0. 14 to 1 42).”
From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [160]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, for the most part, these are of similar efficacy, and many patients are refractory to medical management.”
From Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis (2020) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Guidelines recommend a 'positive' diagnosis using symptom-based diagnostic criteria, such as the Rome criteria, and minimising investigations (Figure 4). 6”
From Irritable bowel syndrome (2020) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The incidence of adverse events with loperamide was similar to placebo in these trials.”
From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [160]
The cited source says what the claim attributes to it.
In the citing paper
“Despite significant heterogeneity between trials, presumably driven by differences in antispasmodics studied, patient selection and study design, fewer patients treated with antispasmodics had persistent global symptoms or abdominal pain (RR 0.65; 95% CI 0.56 to 0.76) (online supple- mental figure 4).”
From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [160]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Hill (2014) · doi:10.1038/nrgastro.2014.66 · Cited by 9,592
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
Self-citationGlobal Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155
Self-citationGershon, M. D., & Tack, J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.002 · Cited by 1,563
O’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O’Sullivan, G. C., Kiely, B., Collins, J. K., Shanahan, F., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.050 · Cited by 1,448
Self-citationA Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome
Halmos, E. P., Power, V. A., Shepherd, S. J., Gibson, P. R., & Muir, J. G. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.09.046 · Cited by 1,249
Research works printed but not linked: 13
- Simren, 2006, Effects of Lactobacillus Plantarum 299V on symptoms and rectal sensitivity in patients with irritable bowel syndrome (IBS) - A randomized double blind controlled trial., Gastroenterology, 130, A600
- Lombardo, 2015, A reason why lactose-free diet can be clinically ineffective in lactose intolerance patients., U Eur Gastroenterol J, 3, A54
- Delmont, 1981, Interet de ladjonction dun antispasmodique musculotrope au traitement des constipations douloureuses des colopathies fonctionnelles par le son., Med Chir Dig, 10, 365
- Virat, 1987, Colopathy pain and dicetel., Prat Med, 43, 32
- Ghidini, 1986, Single drug treatment for irritable colon: Rociverine versus trimebutine maleate., Curr Ther Res Clin Exp, 39, 541
- DArienzo, 1980, DAgostino L. Lottilonio bromuro nel trattamento della sndrome del colon irritabile., Rass Int Clin Ter, 60, 649
- Baldi, 1983, Clinical and functional evaluation of octilonium bromide in the treatment of irritable bowel syndrome: a double-blind controlled trial., Clin Trials J, 20, 77
- Pulpeiro, 2000, Propinox en sindrome de intestino irritable., Prensa Med Argent, 87, 299
- Lech, 1988, Treatment of irritable bowel syndrome with peppermint oil. A double-blind investigation with a placebo., Ugeskr Laege, 150, 2388
- Boerner, 1988, Wirksamkeit und vertraglichkeit eines antidepressivuns beim colon irritabile., Therapiewoche, 38, 201
- Bergmann, 1991, Die therapie des colon irritabile mit trimipramin (Herphonal) - Eine kontrollierte studie., Z Klin Med, 46, 1621
- Vij, 1991, Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients., Indian J Psychiatry, 33, 243
- Fernandez, 1998, Stress and contingency management in the treatment of irritable bowel syndrome., Stress Med, 14, 31, 10.1002/(SICI)1099-1700(199801)14:1<31::AID-SMI754>3.0.CO;2-B · doi:10.1002/(sici)1099-1700(199801)14:1<31::aid-smi754>3.0.co;2-b
Cited by
ACG Clinical Guideline: Management of Irritable Bowel Syndrome
Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001036 · Cited by 893
“94;NNT5 10) (141) and anOR of response to treatment of 1.”
BackgroundInfluentialSelf-citationFord, A. C., Sperber, A. D., Corsetti, M., & Camilleri, M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31548-8 · Cited by 818
Self-citationFord, A. C., Harris, L. A., Lacy, B. E., Quigley, E. M. M., & Moayyedi, P. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15001 · Cited by 619
“The fact that there have been another 18 RCTs of probiotics conducted since the last version of this meta‐analysis, only 4 years ago, underlines the continuing interest in the manipulation of the GI microbiome as a potential therapy for IBS.”
BackgroundInfluentialSelf-citationBritish Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
Self-citation(2011) · SpringerReference · doi:10.1007/springerreference_44317 · Cited by 545
Metadata
- Authors
- Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., & Quigley, E. M. M.
- Affiliations
- University of Leeds (GB)
- McMaster University (CA)
- University of Michigan (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
- Mayo Clinic (US)
- Houston Methodist (US)
- ORCID
- Venue
- American Journal of Gastroenterology
- Published
- 2018-06
- Volume
- 113
- Issue
- Suppl 2
- Pages
- 1-18
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2810026625
- Cited by
- 388
- References
- 271
- Citations by year
- 2026: 24 · 2025: 34 · 2024: 51 · 2023: 35 · 2022: 45 · 2021: 86 · 2020: 57 · 2019: 41 · 2018: 11
- FWCI
- 46.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Funders
- Alimentary Health
- Ipsen
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
- Keywords
- irritable bowel syndrome, functional gastrointestinal disorders, IBS management, physical activity, dietary intervention, dietary fiber, low FODMAP diet, probiotics, prebiotics, gut microbiota, constipation, diarrhea, abdominal pain, quality of life, symptom severity, evidence quality grading, strength of recommendation, consensus building, publication bias, small-study effects, colonic transit
- MeSH terms
- Anti-Bacterial Agents, Antidepressive Agents, Behavior Therapy, Constipation, Diarrhea, Diet, Dietary Fiber, Humans, Parasympatholytics, Plant Oils, Exercise, Randomized Controlled Trials as Topic, Dietary Supplements, Probiotics, Mentha piperita, Irritable Bowel Syndrome, Prebiotics, Synbiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. https://app.cochat.ai/papers/10.1038/s41395-018-0084-x
- The paper
- Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., & Quigley, E. M. M. (2018). American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. American Journal of Gastroenterology. https://doi.org/10.1038/s41395-018-0084-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.